Panel discussion on...
Pet Supplements
Aida Gadzhieva
Associate Principal, RWE and Claims Lead for Consumer Health, IQVIA

Member of AgroFOOD Industry Hi Tech's Scientific Advisory Board

Is there room for innovative pet ingredient development?
4A) The pet supplements sector may expect significant growth over the next decade, yet its long‑term credibility will depend on how effectively the industry responds to the evolving needs, expectations, and experiences of pet owners.
As pets become increasingly integrated into family life, owners are seeking clearer guidance, more transparent claims, and products supported by evidence that reflects the day‑to‑day realities of caring for animals. This shift presents both an opportunity and a challenge: the sector can no longer rely solely on traditional study frameworks or high‑level claims. Instead, companies must ensure that the owner’s perspective - what they observe, value, and are willing to trust - is integrated into how evidence is generated, interpreted, and communicated.
Recent regulatory interactions that we had at IQVIA underscore the consequences of insufficient transparency around evidence generation. Even well‑constructed proposals can face extended clarification cycles when assumptions, methodologies, or relevance to real‑world pet behaviour are not made explicit.
These operational challenges raise a broader question: is the industry well-prepared for providing pet owners with the information critical to their decision-making? Some of the traditional claims may be technically accurate yet fail to resonate with owners because they do not align with observable changes or the practical outcomes owners consider meaningful.
Looking ahead, the sector must adopt a more holistic and owner‑centric approach to evidence planning. This means identifying outcomes that owners genuinely notice (for example, changes in the mobility of the pet, digestive comfort, coat condition, and so on), and ensuring these are embedded into study endpoints, measurement tools, and data interpretation. Real-world owner‑reported outcomes, whether collected through structured observational studies or broader ecosystems of usage data, are essential not because they are “nice to have,” but because they reflect how pets actually live, respond, and improve outside controlled research settings.
Transparency will be key to strengthening trust. Pet owners frequently express confusion about how supplements work, what constitutes credible evidence, and how to distinguish between meaningful claims and marketing noise. Clearer communication, grounded in transparent methodologies and owner‑relevant evidence, will be crucial for improving literacy and enabling informed decision‑making. Companies that prioritize this clarity can help shift the category away from opacity and unsupported claims toward a more trustworthy, responsible model of innovation.
Ultimately, the future success of the pet supplements market will depend on how well the industry listens to pet owners and integrates their real needs into scientific and regulatory workflows. Evidence generation must evolve to reflect the lived experiences of pets and their families, not just laboratory or expert‑driven expectations. By centering the owner’s voice - while maintaining methodological rigor and regulatory transparency - the sector can deliver products that are both scientifically credible and genuinely meaningful in the everyday lives of pets and the people who care for them.
In this Panel Discussion, several prominent companies within the food and nutraceutical ingredient industry have been invited to discuss about drivers and barriers of healthy lifestyle, focusing on global and regional consumer trends, scientific achievements, emerging delivery formats, use of AI technologies and the implementation of the United Nations sustainability goals.
Panelists
References and notes
- Schunck, M. , Louton, H. and Oesser, S. (2017) The Effectiveness of Specific Collagen Peptides on Osteoarthritis in Dogs-Impact on Metabolic Processes in Canine Chondrocytes. Open Journal of Animal Sciences, 7, 254-266. doi: 10.4236/ojas.2017.73020.
- Koivisto et al., 2014; Siebert et al., 2010
- The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients—A translational large animal model for a nutritional therapy option
Dobenecker B, Böswald LF, Reese S, Steigmeier-Raith S, Trillig L, et al. (2024) The oral intake of specific Bioactive Collagen Peptides (BCP) improves gait and quality of life in canine osteoarthritis patients—A translational large animal model for a nutritional therapy option. PLOS ONE 19(9): e0308378. https://doi.org/10.1371/journal.pone.0308378
Questions
1.
2.
3.
4.
Ingredients companies - clinical data
A) What are the main scientific gaps that still exist in PET supplement development compared to human dietary supplements?
B) How important is species-specific research when selecting and developing active ingredients for pets? Can human data ever be sufficient?
C) Is the humanization of pets helping consumers make better-informed choices, or does it risk creating unrealistic expectations about supplement performance?
D) From an ingredient supplier’s perspective, which quality parameters (standardization, bioavailability, purity) are most critical for PET applications?
E) How are trends such as “clean label,” sustainability, and transparency influencing pet owners’ purchasing decisions in the PET supplement space?
F) What type of clinical evidence should realistically be expected to support PET supplement claims today?
G) Which types of claims are most likely to be misunderstood by consumers, and how can this risk be reduced through clearer substantiation and labeling?
H) What are the main methodological challenges in conducting clinical trials for companion animals, and how can they be addressed?
I) How reliable are owner-reported outcomes compared to veterinary assessments, and how should they be integrated into study design?
L) Have you noticed an increasing trend in the use of one (or more) ingredients for pet supplements formulated to promote healthy ageing?
Formulation
A) What are the biggest formulation challenges in PET supplements, particularly regarding palatability, stability, and dosing accuracy?
B) How do formulation choices (e.g., chews, powders, liquids) influence compliance and consistent use from a consumer perspective?
C) Do you see a shift toward simpler, single-ingredient formulations, or are multi-active blends still the dominant approach? Why?
D) How do species differences (dogs vs cats, size, age) influence formulation strategies?
E) Omega 3 alternatives for pet nutrition and sustainability: how do the innovative omega-3s for pet food stack up against their traditional fishy counterparts?
Regulation
A) How do regulatory frameworks for PET supplements differ between the EU and the US, and what challenges do these differences create for global brands?
B) Which types of claims represent the highest regulatory risk today, and which are more likely to be acceptable if properly substantiated?
C) Do you expect regulatory oversight of PET supplements to become stricter in the coming years? Why or why not?
D) What role should veterinarians play in guiding pet owners’ choices regarding PET supplements, and how can trust between brands, vets, and consumers be strengthened?
Open questions
A) Looking ahead 5–10 years, what will be the key factors determining the credibility and long-term success of the PET supplements sector?
B) In your view, what single change—scientific, regulatory, or educational—would most improve consumer trust in PET supplements over the next decade?
References and notes










